Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma

Blood. 2022 Oct 20;140(16):1822-1826. doi: 10.1182/blood.2022015443.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anaplastic Lymphoma Kinase / genetics
  • Humans
  • Lung Neoplasms* / pathology
  • Lymphoma, B-Cell*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Protein Kinase Inhibitors
  • Anaplastic Lymphoma Kinase